GD2-targeted CAR T cells for neuroblastoma
Part of Cancer clinical trials.
This trial tests a special immune cell treatment (GD2-CAR T cells) for children and teens with neuroblastoma that has come back or not responded to standard therapy. It aims to see if these engineered cells can find and attack the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have neuroblastoma that has returned or did not respond to treatment.
- You are between 1 and 17 years old.
- Your major organs (kidneys, liver, heart, lungs) are working well enough.
- You have not had chemotherapy or other cancer treatment for at least 2 weeks.
- Any side effects from past treatments have mostly gone away.
- You are not pregnant and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized CAR-T cell therapy that targets three specific markers (GD2, PSMA, and CD276) on neuroblastoma cells. It is for patients whose cancer has come back or not responded to standard treatment.
This trial tests whether combining your child's own immune cells (NK cells) with a targeted antibody (GD2) can help treat high-risk neuroblastoma. It is for children who are in the maintenance phase, or whose cancer has returned or not responded to standard treatment.
This Phase 1 study tests an experimental CAR T-cell treatment that targets GD2, with added immune-boosting and safety features, for children with relapsed or refractory neuroblastoma or osteosarcoma. It’s designed to see if the treatment is safe and can shrink these cancers when standard therapy hasn’t worked.
This early-phase trial tests an immune-cell treatment made from the child’s own cells, designed to attack neuroblastoma. It aims to help children whose cancer has come back or did not respond to standard treatment.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This trial tests a new type of cell therapy (CAR-NK) that uses your child's own immune cells to attack two different markers on neuroblastoma tumors, called GD2 and B7-H3. It's for children with high-risk neuroblastoma that has come back or hasn't responded to standard treatments.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.